REPL DEADLINE: SueWallSt Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline
Alert: Replimune shares collapsed from a $10.73 Class Period high to $1.70 following the FDA's rejection of the RP1 biologics license application, a cumulative decline of roughly 84% that the complaint alleges followed disclosures correcting earlier statements about the resubmission. NEW...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.